A case of anaplastic thyroid cancer with long-term survival

Anticancer Research

Volumn 30, Issue 4, 2010, Pages 1273-1278

  Koussis, Haralabos ^a   Maruzzo, Marco ^a   Scola, Annamaria ^b   Ide, Eric Casal ^a   Fassina, Ambrogio ^c   Marioni, Gino ^c   Lora, Ornella ^a   Corti, Luigi ^a   Karachontziti, Paraskevi ^d   Jirillo, Antonio ^a  

^a VENETO INSTITUTE OF ONCOLOGY IOV IRCCS   (Italy)

^b Azienda ULSS 12 Veneziana   (Italy)

^c UNIVERSITY OF PADUA MEDICAL SCHOOL   (Italy)

^d IASO   (Greece)

Author keywords

Anaplastic thyroid carcinoma; Case report; Chemotherapy; Long term survival; Multimodal treatment

Indexed keywords

ANTIBIOTIC AGENT; CISPLATIN; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; FENTANYL; NAVELBINE; SUNITINIB;

ADULT; ANAPLASTIC CARCINOMA; ANTIBIOTIC THERAPY; ARTERY COMPRESSION; ARTICLE; ASTHENIA; BLEEDING; BONE NECROSIS; BONE SCINTISCANNING; CANCER CHEMOTHERAPY; CANCER GRADING; CANCER GROWTH; CANCER INVASION; CANCER LOCALIZATION; CANCER SURVIVAL; CASE REPORT; COMPUTER ASSISTED TOMOGRAPHY; COUGHING; DISEASE DURATION; DYSPHAGIA; DYSPNEA; FEBRILE NEUTROPENIA; FEMALE; GLUCOSE TRANSPORT; HOSPITAL ADMISSION; HUMAN; HUMAN TISSUE; LUNG METASTASIS; MULTIMODALITY CANCER THERAPY; MULTIPLE CYCLE TREATMENT; NECK PAIN; NON INSULIN DEPENDENT DIABETES MELLITUS; NUCLEAR MAGNETIC RESONANCE IMAGING; OVARY CYST; OVERALL SURVIVAL; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; SINGLE DRUG DOSE; SURVIVAL TIME; THORAX RADIOGRAPHY; THYROID CARCINOMA; TRACHEAL BIOPSY; TRACHEOTOMY; TREATMENT DURATION; TREATMENT RESPONSE; WEIGHT REDUCTION;

CARCINOMA; COMBINED MODALITY THERAPY; FEMALE; HUMANS; MIDDLE AGED; SURVIVORS; THYROID NEOPLASMS; TREATMENT OUTCOME;

EID: 77953772079     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (29)

1. Are C and Shaha A: Anaplastic thyroid carcinoma: biology, pathogenesis, prognostic factors, and treatment approaches. Annal Surg Onc 13: 453-464, 2006.
2. Ain KB: Anaplastic thyroid carcinoma: behavior, biology, and therapeutic approaches. Thyroid 8: 715-726, 1998.
3. Fraker DI, Skarulis M and Livolsi V: Thyroid tumors. Cancer Principles and Practice of Oncology, 6th Edition. Devita VT, Hellman S and Rosenberg DA (eds.). Philadelphia: Lippincott Williams and Wilkins, pp. 170-1763; 2001.
4. Schlumberger MK: Anaplastic thyroid carcinoma. Orphanet Encyclopedia, March 2004.
5. Gilliland FD, Hunt WC, Morris DM and Key CR: Prognostic factors for thyroid carcinoma. A population-based study of 15,698 cases from the Surveillance, Epidemiology and End Results (SEER) program 1973-1991. Cancer 79: 564-573, 1997.
6. Hadar T, Mor C, Shvero J, Levy R and Segal K: Anaplastic carcinoma of the thyroid. Eur J Surg Oncol 19: 511-516, 1993.
7. Kebebew E, Greenspan F, Clark O, Woeber K and McMillan A: Anaplastic thyroid carcinoma. Treatment outcome and prognostic factors. Cancer 103: 1330-1335, 2005.
8. Brignardello E, Gallo M, Baldi I, Palestini N, Piovesan A, Grossi E, Ciccone G and Boccuzzi G: Anaplastic thyroid carcinoma: clinical outcome of 30 consecutive patients referred to a single institution in the past 5 years. Eur J Endocrinol 156: 425-430, 2007.
9. De Creviosier R, Baudin E, Bachelot A, Leboulleux S, Travagli JP, Caillou B and Schlumberger M: Combined treatment of anaplastic thyroid carcinoma with surgery, chemotherapy, and hyperfractionated accelerated external radiotherapy. Int J Radiat Oncol Biol Phys 60: 1137-1143, 2004.
10. Salvatore G, DeFalco V, Salerno P, Nappi TC, Pepe S, Troncone G, Carlomagno F, Melillo RM, Wilhelm SM and Santoro M: BRAF is a therapeutic target in aggressive thyroid carcinoma. Clin Cancer Res 12: 1623-29, 2006.
11. Ouyang B, Knauf JA, Smith EP, Zhang L, Ramsey T, Yusuff N, Batt D and Fagin JA: Inhibitors of raf kinase activity block growth of thyroid cancer cells with RET/PTC or BRAF mutations in vitro and in vitro. Clin Can Res 12: 1785-93, 2006.
12. Chaplin DJ, Pettit GR and Hill SA: Antivascular approaches to solid tumour therapy: evaluation of combretastatin A4 phosphate. Anticancer Res 19: 189-195, 1999.
13. Landuyt W, Ahmed B, Nuyts S, Theys J, Op de Beeck M, Rijnders A, Anné J, van Oosterom A, van den Bogaert W and Lambin P: In vivo antitumor effect of vascular targeting combined with either ionizing radiation or anti-angiogenesis treatment. Int J Radiat Oncol Biol Phys 49: 443-450, 2001.
14. Siemann DW, Mercer E, Lepler S and Rojiani AM: Vascular targeting agents enhance chemotherapeutic agent activities in solid tumor therapy. Int J Cancer 99: 1-6, 2002.
15. Iyer S, Chaplin DJ, Rosenthal DS, Boulares AH, Li LY and Smulson ME: Induction of apoptosis in proliferating human endothelial cells by the tumor-specific antiangiogenesis agent combretastatin A-4. Cancer Res 58: 4510-4514, 1998.
16. Yeung SC, She M, Yang H, Pan J, Sun L and Chaplin D: Combination chemotherapy including combretastatin A4 phosphate and paclitaxel is effective against anaplastic thyroid cancer in a nude mouse xenograft model. J Clin Endocr Met 92: 2902-2909, 2007.
17. Batori M, Chatelou E, Straniero A and Ruggeri M: Anaplastic Thyroid carcinoma: a case of a young woman that reports a survival exceeding 6 years. Eur Rev Med Pharmacol Sci 77: 69-71, 2007. (Pubitemid 46499180)
18. Kurukahvecioglu O, Ege B, Poyraz A, Tezel E and Taneri F: Anapalstic thyroid carcinoma with long-term survival after combined treatment: case report. Endocr Regul 41: 41-44, 2007.
19. Koussis H, Scola A,Tonello B, Busnardo B, Donach M, Pelizzo M, Toniato A, Mazzarotto E, Mazzarotto R, Karahontzitis P and Monfardini S: Multimodality therapeutic approach in anaplastic thyroid cancer (ATC): study of 56 patients. J Clin Oncol 18(Suppl): abs 5571, 2006.
20. Kihara M, Miyauchi A, Yamauchi A and Yokomise H: Prognostic factors of anaplastic thyroid carcinoma. Surg Today 34: 394-398, 2004.
21. Bernier J and Vrieling C: Docetaxel in the management of patients with head and neck squamous cell carcinoma. Expert Rev Anticancer Ther 8(7): 1023-1032, 2008.
22. Mendel DB, Laird AD, Xin X, Louie SG, Christensen JG, Li G, Schreck RE, Abrams TJ, Ngai TJ, Lee LB, Murray LJ, Carver J, Chan E, Moss KG, Haznedar JO, Sukbuntherng J, Blake RA, Sun L, Tang C, Miller T, Shirazian S, McMahon G and Cherrington JM: In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship. Clin Cancer Res 9(1): 327-337, 2003.
23. Ravaud A, de la Fouchardière C, Courbon F, Asselineau J, Klein M, Nicoli-Sire P, Bournaud C, Delord J, Weryha G and Catargi B: Sunitinib in patients with refractory advanced thyroid cancer: the THYSU phase II trial. J Clin Oncol 26: (suppl; abstr 6058), 2008.
24. Voigt W, Kegel T, Weiss M, Mueller T, Simon H and Schmoll HJ: Potential activity of paclitaxel, vinorelbine and gemcitabine in anaplastic thyroid carcinoma. J Cancer Res Clin Oncol 131: 585-590, 2005.
25. Ain KB, Tofiq S and Taylor KD: Antineoplastic activity of taxol against human anaplastic thyroid carcinoma cell lines in vitro and in vivo. J Clin Endocrinol Metab 81(10): 3650-3653, 1996.
26. Ain KB, Egorin M and DeSimone P: Treatment of anaplastic thyroid carcinoma with paclitaxel: phase 2 trial using ninety-six-hour infusion. Thyroid 10: 587-594, 2000.
27. Patel KN and Shaha AR: Poorly differentiated and anaplastic thyroid cancer. Cancer Control 13: 119-128, 2006.
28. Ikeda M, Tanaka K, Sonoo H, Miyake A, Yamamoto Y, Shiiki S, Nakashima K and Kurebayashi J: Docetaxel administration for radioiodine-resistant patients with metastatic papillary thyroid carcinoma. J. Gan To Kagaku Ryoho 34(6): 933-936, 2007.
29. Green LD, Mack L and Pasieka JL: Anaplastic thyroid cancer and primary thyroid lymphoma: a review of these rare thyroid malignancies. J Surg Oncol 94(8): 725-736, 2006.